Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Medtronic
Mallinckrodt
McKesson
Moodys

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Litigation Details for SmithKline Beecham Corporation v. Eon Labs Manufacturing, Inc. (E.D.N.Y 1998)

See Plans and Pricing

« Back to Dashboard

SmithKline Beecham Corporation v. Eon Labs Manufacturing, Inc. (E.D.N.Y 1998)

Docket   Start Trial Date Filed 1998-03-06
Court District Court, E.D. New York Date Terminated 1998-09-17
Cause 35:271 Patent Infringement Assigned To Charles Proctor Sifton
Jury Demand None Referred To Magistrate Judge A. Simon Chre
Parties BEECHAM GROUP, P.L.C; EON LABS MANUFACTURING, INC.; SMITHKLINE BEECHAM CORPORATION
Patents 4,420,639
Attorneys Catriona M. Collins; Henry J. Renk; Myron Cohen; Robert L. Baechtold; Steven J. Bosses; Vincent M. Fazzari; Yunling Ren
Firms Cohen & Gresser LLP; Cohen, Pontani, Lieberman & Pavane; Fitzpatrick, Cella, Harper & Scinto
Link to Docket External link to docket
Small Molecule Drugs cited in SmithKline Beecham Corporation v. Eon Labs Manufacturing, Inc.
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for SmithKline Beecham Corporation v. Eon Labs Manufacturing, Inc. (E.D.N.Y 1998)

Date Filed Document No. Description Snippet Link To Document
1998-03-06 1 Group is the owner of United States Patent No. 4,420,639 (“the ’639 Patent"), which discloses and claims…claimed in the ’639 Patent before the patent’s expiration, Eon has infringed the ’639 Patent pursuant to 35… the United States Patent and Trademark Office extended the term of the ’639 Patent for a period of two…PagelD #: 3 copy of the ’639 Patent and Certificate Extending The Patent Term is attached as Exhibit … ’639 Patent. lO. On information and belief, Eon was aware of the existence of the ’639 Patent and was External link to document
1998-03-13 4 5. Eon denies that U.S. Patent No. 4,420,639 ("the ’639 Patent") was duly and legally issued…AFFIRMATIVE DEFENSE 12. U.S. Patent No. 4,420,639 ("the ’639 Patent) is invalid because of its failure…declaratory judgment that U.S. Patent No. 4,420,639 (the " ’639 Patent") is invalid and/or unenforceable…639 patent is unenforceable by reason of Beecham’s breach of the duty of candor to the U.S. Patent and…accusing it of infringement of the ’639 Patent. 7. The ’639 Patent is invalid under one or more sections External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Merck
Express Scripts
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.